1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY

4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
4.5.2. CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
4.5.3. INCREASING ELDERLY POPULATION
4.5.4. IMPROVED AND EFFICIENT DRUGS IN PIPELINE
4.5.5. INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
4.6. RESTRAINTS
4.6.1. SURGICAL TREATMENTS
4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
4.7.1. HIGH UNMET NEEDS
4.8. CHALLENGES
4.8.1. SIDE EFFECTS OF CIC DRUGS

5. NORTH AMERICA CIC DRUGS MARKET, BY DRUG TYPE 2018-2026 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. OTHERS
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)

6. NORTH AMERICA CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.2. OVER THE COUNTER DRUGS

7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRY
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX

8. NORTH AMERICA CIC DRUGS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
8.1. US
8.2. CANADA

9. COMPANY PROFILES
9.1. ALLERGENS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. CHUGAI PHARMACEUTICAL
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. FERRING INTERNATIONAL CENTER S.A.
9.3.1. OVERVIEW
9.3.2. PRODUCTS PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.5. PFIZER
9.5.1. OVERVIEW
9.5.2. PFIZER PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. GLAXOSMITHKLINE
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. ROCHE HOLDING AG
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. SANOFI
9.8.1. OVERVIEW
9.8.2. PRODUCTS PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. BAYER AG
9.9.1. OVERVIEW
9.9.2. PRODUCTS PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MERCK SHARP & DOHME
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. ELI LILLY AND COMPANY
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. SALIX PHARMACEUTICALS LTD
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.13. SUCAMPO PHARMACEUTICALS INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.14. IRONWOOD PHARMACEUTICALS INC
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.15. VALEANT PHARMACEUTICALS INTERNATIONAL
9.15.1. OVERVIEW
9.16. DAIICHI SANKYO CO LTD
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.17. COSMO PHARMACEUTICALS SA
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.18. PROGENICS PHARMACEUTICALS INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.19. THERAVANCE BIOPHARMA INC
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS

LIST OF TABLES
TABLE 1 NORTH AMERICA CIC DRUG MARKET BY COUNTRIES 2018-2026 ($ MILLION)
TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION
TABLE 3 CONSTIPATION IN PARKINSON'S DISEASE
TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION
TABLE 5 NORTH AMERICA CIC DRUGS MARKET BY DRUG TYPE 2018-2026 ($ MILLION)
TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 7 PRODUCT PROFILE (LINACLOTIDE)
TABLE 8 PRODUCT PROFILE (BISACODYL)
TABLE 9 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 10 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 11 NORTH AMERICA CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 12 LINZESS PRECAUTIONS AND SIDE EFFECTS
TABLE 13 NORTH AMERICA CIC DRUGS MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 14 U.S. CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 15 U.S. CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)
TABLE 16 CANADA CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 17 CANADA CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)

LIST OF FIGURES
FIGURE 1 NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 2 NORTH AMERICA CIC DRUG MARKET BY DRUG TYPE 2018-2026 ($ MILLION)
FIGURE 3 NORTH AMERICA CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2017 ($ MILLION)
FIGURE 4 CAUSES OF CONSTIPATION
FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014
FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE
FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS
FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION
FIGURE 9 NEED OF SURGERY PROCESS
FIGURE 10 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM
FIGURE 11 NORTH AMERICA LUBIPROSTONE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 12 NORTH AMERICA LINACLOTIDE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 13 NORTH AMERICA OTHER DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 14 NORTH AMERICA PRESCRIBED CIC DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 15 NORTH AMERICA OVER THE COUNTER CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 16 NORTH AMERICA CIC DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 17 US CIC MARKET, 2018-2026 ($ MILLION)
FIGURE 18 CANADA CIC MARKET 2018-2026 ($ MILLION)